Emergency use of eculizumab in impending and manifest myasthenic crisis: a retrospective case series
Therapeutic Advances in Neurological Disorders
Published online on February 26, 2026
Abstract
Therapeutic Advances in Neurological Disorders, Volume 19, January-December 2026.
Impending and manifest myasthenic crisis (MC) represent life-threatening neurological emergencies that require immediate intervention. Although eculizumab, a terminal complement C5 inhibitor, has established efficacy in generalized myasthenia gravis, most ...
Impending and manifest myasthenic crisis (MC) represent life-threatening neurological emergencies that require immediate intervention. Although eculizumab, a terminal complement C5 inhibitor, has established efficacy in generalized myasthenia gravis, most ...